Biopharmaceutical company Array BioPharma is planning to stop the MILO study, which is an international, randomised phase 3 trial of binimetinib for treatment of patients with low-grade serous ovarian cancer.

After undertaking a planned interim analysis, which revealed that the Hazard Ratio for Progression Free Survival (PFS) crossed the predefined futility boundary, Array decided to discontinue the study.

Array stated that it will work with investigators to appropriately conclude the MILO study in a way that considers the best interest of each patient, while more detailed results will be shared with the scientific community in the future.

"While we are disappointed by this outcome, the findings from MILO have no impact on the other studies of binimetinib."

Array chief medical officer Victor Sandor said: "While we are disappointed by this outcome, the findings from MILO have no impact on the other studies of binimetinib, including the NEMO trial, which has already met its primary endpoint, and the COLUMBUS trial, which is designed to test a highly precedented combination of mechanisms in patients with BRAF-mutant melanoma."

All other current studies of binimetinib, such as the Phase 3 BRAF-mutant melanoma (COLUMBUS) and NRAS-mutant melanoma (NEMO) trials, will be continued.

Top-line results from the study had been expected in 2017.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary endpoint is PFS and secondary endpoints cover overall survival, overall response rate, duration of response, disease control rate, safety and quality of life.

Binimetinib is in late-stage of development, with a primary phase 3 programme (COLUMBUS) in BRAF-mutant melanoma in combination with BRAF inhibitor, encorafenib.

The drug is also being investigated in a phase 3 study (NEMO) in patients suffering from NRAS-mutant melanoma.